Horizon Discovery plc Entrate Q/Q
Cos'è Entrate Q/Q di Horizon Discovery plc?
Entrate Q/Q di Horizon Discovery Group plc è -21.40%
Qual è la definizione di Entrate Q/Q?
La crescita trimestrale dei ricavi, anno su anno , è l'aumento delle entrate di un'azienda rispetto alla performance nel corrispondente trimestre dell'anno precedente espresso in percentuale.
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Entrate Q/Q di aziende nel Health Care settore su LSE rispetto a Horizon Discovery plc
Cosa fa Horizon Discovery plc?
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Aziende con entrate q/q simili a Horizon Discovery plc
- Rana Sugars ha Entrate Q/Q di -21.44%
- Clariant AG ha Entrate Q/Q di -21.44%
- Daimler AG ha Entrate Q/Q di -21.43%
- First Savings Inc ha Entrate Q/Q di -21.43%
- Pimco New York Municipal Income Fund ha Entrate Q/Q di -21.42%
- good natured Products ha Entrate Q/Q di -21.41%
- Horizon Discovery plc ha Entrate Q/Q di -21.40%
- China Rapid Finance ha Entrate Q/Q di -21.39%
- Balkrishna Industries ha Entrate Q/Q di -21.38%
- EDAG Engineering AG ha Entrate Q/Q di -21.37%
- AB Builders ha Entrate Q/Q di -21.36%
- Algoma Steel ha Entrate Q/Q di -21.36%
- Bounty Oil & Gas NL ha Entrate Q/Q di -21.35%